Skip to content
Screener

Net Income at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$4.89M-102%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$2.81M-100%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$8.75M-88.3%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-$100.7M+10.1%
Regenxbio logo
RegenxbioRGNX
$22.71M+132%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$166.56M+1.8%

Segments

By segment

See full
Reportable Segment$44.76M-81.4%

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$11.58B-0.6%
Enterprise value$14.89B+34.9%
P/E32.2×-34.7×
P/S3.4×-0.4×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Other income, net3,2794,8337,2402,879
INCOME BEFORE INCOME TAXES61,384297,868202,587535,957
Provision for income taxes16,62257,33652,298109,739
NET INCOME$44,762$240,532$150,289$426,218
EARNINGS PER SHARE, BASIC$0.23$1.25$0.78$2.23
EARNINGS PER SHARE, DILUTED$0.23$1.23$0.77$2.19
Weighted average common shares outstanding, basic193,423191,907192,959191,440
Weighted average common shares outstanding, diluted194,467197,091194,147196,643

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's net income?
BioMarin Pharmaceuticals (BMRN) reported net income of $44.76M in Q2 2026.
How has BioMarin Pharmaceuticals's net income changed year-over-year?
BioMarin Pharmaceuticals's net income decreased by 81.4% year-over-year, from $240.53M to $44.76M.
What is the long-term trend for BioMarin Pharmaceuticals's net income?
Over 3 years (2021 to 2024), BioMarin Pharmaceuticals's net income has grown at a 88.2% compound annual growth rate (CAGR), from -$64.08M to $426.86M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about BioMarin Pharmaceuticals's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude